Study Finds Semaglutide Reduces Fracture Risk While Promoting Weight Loss
Study Highlights Bone Protective Effects of Semaglutide
New research suggests semaglutide, the active ingredient in popular diabetes and weight-loss drugs like Ozempic, Wegovy, and Rybelsus, may offer unexpected skeletal benefits alongside its weight reduction effects.
Researchers analyzed health records from nearly 60,000 adults and found that patients taking semaglutide experienced approximately 15% fewer bone fractures than those using other common weight-loss medications. This finding is particularly notable given that the semaglutide group achieved greater weight loss—a factor that has traditionally been associated with increased fracture risk due to reduced bone density.
The study's authors describe this as a real-world investigation, meaning the findings reflect how the medication performs in routine clinical practice rather than controlled trial settings. The results suggest semaglutide may provide protective effects for bone health that warrant further investigation, especially for populations at higher risk of fractures.